[Massive myocardial hypertrophy in hypertrophic cardiomyopathy: a risk factor for sudden death and high defibrillation threshold during cardioverter-defibrillator implantation].

Two cases of hypertrophic cardiomyopathy with massive hypertrophy and high defibrillation threshold (DFT) are described. A 14-year-old boy, whose single risk factor for sudden death was extreme hypertrophy with maximum interventricular septum (IVS) thickness of 43 mm, survived an episode of ventricular fibrillation. During ICD implantation DFT testing showed energy requirements >30 J and the procedure was aborted. Amiodarone and verapamil treatment was discontinued and treatment with oral sotalol was instituted. After a period of amiodarone washout the procedure was repeated and DFT of 24 J was encountered. An 18-year-old female with massive hypertrophy (IVS thickness=35 mm) and other risk factors for sudden death underwent ICD implantation for primary prevention. During the procedure DFT=20 J and ICD with 30 J maximal output was implanted. An increase in DFT to more than 20 J was encountered during pre-discharge test. Lack of 10 J safety margin warranted ICD system revision and upgrade; during the second procedure DFT was 24 J and ICD with 35 J maximal output was implanted. In summary, in both cases ICDs with 35 J maximal output were successfully implanted.

[1]  G. Boriani,et al.  Prevention of Sudden Death in Hypertrophic Cardiomyopathy: But Which Defibrillator for Which Patient? , 2004, Circulation.

[2]  C. Tracy,et al.  American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, European heart journal.

[3]  M. Link,et al.  Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. , 2003, Circulation.

[4]  B. Maron,et al.  Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. , 2003, The American journal of cardiology.

[5]  V. Jayam,et al.  High Defibrillation Thresholds in Transvenous Biphasic Implantable Defibrillators: , 2003, Pacing and clinical electrophysiology : PACE.

[6]  R. Kerber,et al.  ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices , 2002 .

[7]  R. Kerber,et al.  ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). , 2002, Circulation.

[8]  G. Boriani,et al.  Hypertrophic cardiomyopathy with massive hypertrophy, amiodarone treatment and high defibrillation threshold at cardioverter-defibrillator implant. , 2002, International Journal of Cardiology.

[9]  M. Gold,et al.  Clinical Predictors of Defibrillation Thresholds with an Active Pectoral Pulse Generator Lead System , 2002, Pacing and clinical electrophysiology : PACE.

[10]  Thomas D. Nielsen,et al.  Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. , 2001, The American journal of cardiology.

[11]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[12]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[13]  G. Boriani,et al.  High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: favorable effects of D, L-sotalol. , 2000, Heart & lung : the journal of critical care.

[14]  F. Morady,et al.  Effect of Chronic Amiodarone Therapy on Defibrillation Energy Requirements in Humans , 2000, Journal of cardiovascular electrophysiology.

[15]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[16]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[17]  R. Peters,et al.  Clinical predictors of transvenous defibrillation energy requirements. , 1997, The American journal of cardiology.

[18]  P. Dorian,et al.  d‐Sotalol Decreases Defibrillation Energy Requirements in Humans: , 1996, Journal of cardiovascular electrophysiology.

[19]  F. Marchlinski,et al.  Early Postoperative Rise in Defibrillation Threshold in Patients with Nonthoracotomy Defibrillation Lead Systems: , 1996, Journal of cardiovascular electrophysiology.